v3 Template
T

TRIMTECH Therapeutics

Biotechnology / Healthcare ~320 employees
Founded
--
Employees (Est.)
~320
16 leaders known
Total Funding
$31.0M
Funding Rounds
1
Last Funding
2025-03-05

About TRIMTECH Therapeutics

Trimtech Therapeutics is focused on developing transformative treatments for CNS and inflammatory disorders by selectively destroying disease-causing protein aggregates. They aim to create a differentiated portfolio of potent, highly specific degraders known as TRIMTACs™ and TRIMGLUEs™ for the treatment of intractable conditions.

Products & Services

TRIMTACs™:Highly specific degraders targeting the removal of toxic proteins for treating CNS and inflammatory disorders.

Specialties

Targeted Protein Degradation CNS Disorders Treatment Inflammatory Disorders Treatment TRIM21 Research Neurodegenerative Diseases

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Seed
T: -
FT: Seed 		A: 31000000
MR: -
FA: $31 million
FAN: 31000000 		D: 2025-03-05
FD: 2025-03-05 		8 investors
Seed Latest
2025-03-05
$31.0M
8 investors (Pro only)

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

M

Michael Anstey, PhD

Non-Executive Director

L

Laurence Barker, MBA PhD

Non-Executive Director

M

Marie-Claire Peakman, MRPharmS PhD

Non-Executive Director

J

Jeffrey Moore, MBA DPhil

Non-Executive Director

H

Hakan Goker, PhD

Non-Executive Director

N

Nicki Thompson, PhD

CEO

View 13 more team members with Pro

Unlock Full Team Directory

Recent News

TRIMTECH Therapeutics Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biotechnology / Healthcare
Company Size
~320 employees (est.)

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro